Objective: To summarize results from pain and opioid use assessments with naloxegol in adults with opioid-induced constipation (OIC) and chronic noncancer pain. Methods: Two phase 3 randomized, double-blind, 12-week studies evaluated the efficacy and safety of oral naloxegol (12.5 or 25 mg daily) in adults (18 to < 85 years) with confirmed OIC and chronic noncancer pain: KODIAC-04 (NCT01309841) and KODIAC-05 (NCT01323790). Pain level was assessed daily (11-point numeric rating scale [NRS]; 0 = no pain, 10 = worst imaginable pain). Changes from baseline in mean weekly pain scores and opioid dose (weeks 1 through 12) were analyzed using mixed-model repeated measures.
INTRODUCTION
Opioid analgesics constitute a long-standing, widely used strategy for the treatment of chronic pain.
Although the evidence that informs the opioid treatment landscape is still evolving, a multidisciplinary panel convened by the American Pain Society and the American Academy of Pain Medicine has developed evidencebased guidelines regarding the appropriate use of such analgesics for the management of chronic noncancer pain in adults. 2 Specifically, panel recommendations declare that clinicians may consider chronic opioid therapy "if chronic noncancer pain is moderate or severe, pain is having an adverse impact on function or quality of life, and potential therapeutic benefits outweigh or are likely to outweigh potential harms." 2 Opioids are considered a treatment option for patients with moderate to severe chronic noncancer pain resulting from a variety of causes, including low back pain, neuropathic pain, and osteoarthritis-related pain. 3 The analgesic effect of opioids occurs via actions at receptors in both the central nervous system (CNS) 4, 5 and the peripheral nervous system. 5, 6 However, because opioid analgesics also act at receptors in the gastrointestinal (GI) tract that mediate a variety of functions, including GI motility and secretion, 7 individuals who take these agents are at risk for experiencing opioidinduced bowel dysfunction. 8 One significant manifestation of such is opioid-induced constipation (OIC), a condition in which gut motility and secretions are reduced, leading to a variety of symptoms, including hard, dry stools; rectal straining; and incomplete evacuation. 9 , 10 The prevalence of OIC in such patients ranges between 40% and 80%. [11] [12] [13] The presence of OIC can also cause suboptimal analgesic dosing and result in inadequate pain relief. 11, 14 For example, in a 2009 study by Bell et al., 11 33% of patients reported reducing, interrupting, or ceasing their intake of opioid analgesics in an effort to have a bowel movement (BM). The resulting inadequate pain relief can negatively affect quality of life, as well as an individual's ability to participate in activities of daily living.
11 Patients generally do not develop tolerance to OIC, in contrast to the tolerance that develops to opioid-induced nausea, vomiting, sedation, and respiratory depression.
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The use of laxatives in this context fails to target the cause of OIC, and provides only limited relief of constipation and other GI symptoms.
11, 15 Indeed, approximately one half of patients in a small, observational pilot study conducted in the Netherlands were classified as nonresponders to standard laxatives. 16 Recent treatment strategies for OIC use oral and subcutaneous agents that employ different mechanisms of action. Chloride channel stimulators, such as the orally administered CIC-2 activator lubiprostone, act to stimulate fluid secretion in the intestine. [17] [18] [19] Peripherally acting l-opioid receptor antagonists (PAMORAs), such as naloxegol and methylnaltrexone, selectively target l-opioid receptors in the GI tract and have limited ability to penetrate the CNS. 15, [20] [21] [22] [23] Their ability to cross the blood-brain barrier is restricted owing to characteristics of their respective molecular structures: naloxegol is a PEGylated naloxone derivative, and methylnaltrexone is a methylated naltrexone derivative characterized by high polarity and low lipid solubility.
22,24 As a PEGylated naloxone derivative, naloxegol also has the potential for efflux across the blood-brain barrier, which may also minimize CNS exposure. In the United States, lubiprostone, naloxegol, and oral methylnaltrexone are approved for the treatment of OIC in adults with chronic noncancer pain, 19,21,23 while subcutaneous methylnaltrexone is approved for OIC treatment in patients with chronic noncancer pain as well as in patients with advanced illness receiving palliative care with an insufficient response to laxatives.
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Two identical 12-week, phase 3 studies, KODIAC-04 and KODIAC-05, investigated the efficacy and safety of daily doses of naloxegol (12.5 mg or 25 mg) vs. placebo in patients with OIC. 20 To support the mechanism of action of naloxegol as a PAMORA, particularly its lack of effect on centrally mediated opioid analgesia, detailed analyses of pain-related data from these 2 studies were performed, including integrated analyses of patient-level pain and opioid usage data. Here, we present the results of those analyses of patient-level pain and opioid usage. 25 in ≥ 25% of BMs) during the 2 weeks before randomization. Patients were excluded from participation in these studies if they were taking an opioid analgesic as treatment for cancer-related pain; experienced constipation unrelated to opioid use; had other GI-related conditions associated with weakened bowel integrity and/or bowel obstruction; or experienced severe background pain (typical average numeric rating scale [NRS] score of 8 to 10) 26 refractory to opioid therapy. Both studies were designed to ensure that ≥ 50% of enrolled patients were those who had experienced a laxative-inadequate response. Patients taking methadone for maintenance treatment of opioid addiction, mixed opioid agonist/antagonist agents, opioid agonist/antagonist combination drugs, and other PAMORAs were excluded from participation in both studies.
METHODS

Study Design and Participants
Assessments
Changes from baseline in mean weekly pain scores and mean daily opioid doses during study weeks 1 through 12 were assessed. Changes from baseline in mean weekly pain scores were measured using an 11-point NRS (0 = no pain; 10 = worst imaginable pain). 26 Each evening, patients used an electronic diary to record what they considered their "average pain" and their "worst pain" during the previous 24 hours. The mean weekly NRS scores for patients' average pain and worst pain were calculated based on these respective daily ratings. A score reduction of approximately 2 points was considered to represent a clinically important change at the individual patient level. 26 Investigators were provided with an opioid dose change form to indicate the main reason for any change in maintenance opioid dose during the study. The form listed common reasons for increasing or decreasing a patient's opioid dose, such as inadequate (or improved) pain control, tolerance to analgesic effect, opioid rotation, difficulty tolerating an opioid at a particular dose level, or changes in the dosing of a concomitant nonopioid analgesic medication. Multiple responses were possible.
Statistical Analysis
Descriptive statistics were employed to summarize the observed values, as well as the changes in pain scores and daily opioid doses from baseline during weeks 1 through 12. A prespecified mixed-model, repeatedmeasures approach was used to analyze the changes of these endpoints from baseline. These analyses were conducted for patients in the intent-to-treat population who had received ≥ 1 dose of naloxegol. We also present least squares (LS) mean estimates of the difference vs. placebo, with 95% confidence intervals (CIs) and nominal P values. Statements of statistical significance are based on nominal 2-sided P values < 0.05, with no adjustment for multiplicity.
RESULTS
Study Participants
KODIAC-04 screened 1,750 patients for randomization (n = 652 randomized; mean age 52.3 years; 80.4% completion rate), and KODIAC-05 screened 1,969 patients for randomization (n = 700 randomized; mean age 52.1 years; 76.7% completion rate). 20 It was necessary that study participants be exhibiting OIC for 2 weeks prior to randomization and receiving a stable maintenance regimen for analgesia, with no expected change in dosage for the study duration; therefore, patients without confirmation of OIC or whose pain was not adequately controlled by opioid analgesic therapy were excluded. 20 Overall, approximately two thirds of randomized patients in both studies were women and approximately 80% were white. Forty-eight percent of patients in KODIAC-04 and 50.7% of patients in KODIAC-05 had a body mass index (BMI) between 18.5 and < 30.5 kg/m, 2 while 51.6% and 47.7%, respectively, had a BMI ≥ 30 kg/m 2 ; less than 1% of patients in KODIAC-04 and KODIAC-05 combined had a BMI < 18.5 kg/m 2 (KODIAC-04: 0.3%; KODIAC-05: 1.1%). Each BMI category was represented similarly among all arms of both studies.
The conditions most commonly reported by patients in KODIAC-04 and KODIAC-05 as the primary reason for pain were back pain (56.0% and 56.8%, respectively), joint pain/arthritis (13.4% and 15.1%), and fibromyalgia/neuralgia (6.7% and 9.1%). 20 The overall mean duration of current opioid use reported by patients was 3 to 4 years. 20 On average, patients reported < 2 SBMs per week. 20 In KODIAC-04, the weekly number of SBMs recorded each week from weeks 1 through 12 ranged from 3.9 to 4.3 with naloxegol 12.5 mg and from 4.0 to 4.9 with naloxegol 25 mg, compared to a range of 3.0 to 3.8 with placebo. Over the 12 weeks of 
*Maintenance opioid medications during the baseline period were defined as those taken by patients before the first dose of naloxegol or placebo and ongoing or started on/later than the À14 study day or visit 2 up to the À1 study day. † A patient taking the same medication multiple times is only counted once within a particular anatomical-therapeuticchemical (ATC) classification (preferred term). The same patient may be counted multiple times if different classes of opioids were taken.
‡ Patients who were receiving methadone for maintenance of opioid addiction were excluded from the present study; patients who were receiving methadone for pain management were eligible for participation in this study. ITT, intent to treat. treatment, the mean number of SBMs in KODIAC-04 was 4.0, 4.5, and 3.4 with naloxegol 12.5 mg, naloxegol 25 mg, and placebo, respectively. In KODIAC-05, the weekly frequency of SBMs ranged from 3.8 to 4.3 with naloxegol 12.5 mg and from 4.2 to 4.7 with naloxegol 25 mg, compared to a range of 3.0 to 3.9 with placebo. Over the 12 weeks of treatment, the mean number of SBMs in KODIAC-05 was 4.1, 4.5, and 3.5 with naloxegol 12.5 mg, naloxegol 25 mg, and placebo, respectively. 20 The most commonly used opioid medications at baseline were oxycodone, hydrocodone, and morphine (see Table 1 ).
Pain Scores
Changes from baseline in average and worst pain scores are summarized in Table 2 . At baseline, mean average pain scores reflected a moderate level of pain intensity across treatment groups in both studies (despite concomitant opioid therapy). Mean weekly pain scores were similar and remained stable throughout 12 weeks of study treatment. Patients reported mean average pain reductions of 0.0 to 0.3 points, as well as mean worst pain reductions of 0 to 0.2 points. LS mean estimates for average and worst pain scores were similar and did not differ significantly between naloxegol treatment groups and placebo (see Table 2 and Figure 1 ). The 2-sided 95% CIs of the difference in LS means (naloxegol/placebo) ranged from À0.24 to +0.23 in KODIAC-04 and from À0.22 to +0.24 in KODIAC-05, which excludes a clinically relevant difference in mean NRS pain scores between naloxegoltreated and placebo patient groups of 1 point, as suggested by the literature. 27 Figure 2 presents the highest (top panels) and lowest (bottom panels) weekly on-treatment values vs. the baseline value of the NRS average pain scores for each patient by treatment group. Across both studies combined, the proportions of patients with increases in NRS mean weekly pain scores of ≥ 2 for patients treated with placebo, naloxegol 12.5 mg, or naloxegol 25 mg was 8.3% (n = 37/444), 7.9% (n = 35/441), and 9.6% (n = 43/446), respectively.
Daily Opioid Use
Mean daily opioid doses for both studies at baseline and changes from baseline during weeks 1 to 12 are presented in Table 3 and Figure 3 . The LS mean estimates for daily opioid doses were similar and not statistically different between naloxegol groups and placebo (see Figure 3) . Mean daily opioid doses were similar among all arms of both studies, and remained stable throughout 12 weeks of treatment.
Investigators reported few changes in patients' maintenance opioid doses during the studies. Across treatment groups, no relevant differences were observed A KODIAC-04 regarding the distribution of reasons for changes in maintenance opioids, the most common reason being inadequate pain relief (see Table 4 ).
DISCUSSION
The main results of these 2 randomized, double-blind, placebo-controlled phase 3 studies regarding the efficacy and safety of naloxegol at 12.5-mg and 25-mg doses have been presented by Chey et al. 20 In addition, these 2 studies observed patient-reported pain scores and opioid dosing; because naloxegol targets the cause of OIC through a peripheral site of action, it was expected that naloxegol would not be associated with reversal of analgesia or changes to opioid dosing. 28 During the 12-week study period, naloxegol 12.5 mg and 25 mg increased the frequency of SBMs, but did not produce clinically relevant changes in patient-reported pain scores or daily opioid doses compared with placebo. As mentioned previously, additional detailed analyses of patient-level pain and opioid usage data were performed. This article elaborates on those analyses of individual patient-level data, including outlier data, as opposed to the mean pain score data for the overall population reported by Chey et al. 20 The NRS is the preferred instrument to evaluate treatments for chronic pain, 29 and a clinically relevant change in pain score at the individual patient level is typically considered to be a 2-point difference, 26 or an approximate change of 30%. 26, 29 When naloxegol was evaluated in a controlled fashion in patients with OIC and chronic noncancer pain, as part of the KODIAC-04 and KODIAC-05 studies, mean changes in pain scores were ≤ 0.3 points for average pain and ≤ 0.2 points for worst pain. For both evaluations of pain, changes were similar across treatment groups within and across studies (see Table 2 ). Moreover, the proportion of naloxegol-treated patients with a clinically relevant change in pain score was low and comparable to that observed with placebo. Such findings contrast with those of low-dose naloxone, which crosses the blood-brain barrier and leads to reversal of analgesia in some patients. 30, 31 Maintenance of analgesia during treatment with naloxegol in this patient population was also supported by a low mean change from baseline in daily opioid dose of < 3 morphine equivalent units per day across treatment groups; the median change from baseline was 0 across treatment groups (see Table 3 ). Although some changes in NRS pain scores and opioid dosing were observed, as a group the NRS pain scores and opioid doses associated with naloxegol administration were stable and comparable to those associated with placebo. 20 Taken together, the observed stability of pain scores and opioid doses supports the peripheral site of action of naloxegol (indicated by the improvement in the frequency of SBMs), and indicates that centrally mediated analgesia was maintained in naloxegol-treated patients throughout these 2 studies. 20 The combined use of daily diary assessments, employment of the NRS to evaluate pain severity, and monitoring of opioid usage to measure changes relative to baseline throughout the study periods in patients with noncancer pain constitutes a particular strength of KODIAC-04 and KODIAC-05. As mentioned above, the NRS is a recommended measure of chronic pain in clinical trials. 29 The randomized controlled trials of lubiprostone reported maintenance of analgesia over time using the Brief Pain Inventory-Short Form, 17,18 but only 1 study assessed opioid use. 18 Studies of the effect of methylnaltrexone also monitored pain intensity and found preservation of analgesia; however, the studies in patients with noncancer pain did not include daily pain assessments and did not report temporal data for opioid use. 22 Studies of methylnaltrexone in patients with advanced illness also did not assess pain on a daily basis. 32, 33 Although both KODIAC-04 and KODIAC-05 included patients whose pain was being treated with a variety of opioid drugs from several opioid classes (see Table 1 ), neither was designed to formally assess drug-or drug class-specific variations in patients' experience of pain. Therefore, it remains unknown whether (and if so, to what extent) particular opioids or opioid classes are better suited to coadministration with naloxegol in order to best maintain pain relief while minimizing OIC symptoms. In addition, although patients with pain histories arising from different etiologies (eg, neuropathic pain vs. arthritic pain vs. back pain) were included in these studies, the majority of the patient populations suffered from low back pain and the studies were not adequately powered to statistically analyze differences in pain scores or opioid dosing with respect to various pain types.
CONCLUSION
Naloxegol does not have a clinically relevant effect on patient-reported pain levels or mean daily opioid dose in patients with noncancer pain and OIC. In parallel, changes in maintenance opioid dose were few and not clinically relevant. These findings, based on aggregate individual data, therefore indicate that centrally mediated opioid analgesia is maintained during treatment with naloxegol in patients with noncancer pain and OIC. These results are consistent with the peripheral site of action of naloxegol, as opposed to systemic opioid antagonists, which is also apparent in terms of improved frequency of SBMs. Whether patients with chronic pain due to various etiologies experience etiology-specific shifts in pain scores or require condition-specific opioid dosing adjustments to maintain analgesia when naloxegol is used to treat OIC remains an unanswered question. Although individual variability is associated with most drugs, it is still too early to draw conclusions about whether the appropriate dose of naloxegol will vary in the real-world setting, where additional variables might have an effect on clinical effectiveness. It will be interesting to determine whether these findings hold across a variety of chronic pain etiologies. 
